<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613520</url>
  </required_header>
  <id_info>
    <org_study_id>BSPZV2</org_study_id>
    <nct_id>NCT02613520</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants</brief_title>
  <official_title>Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium Falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanaria Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ifakara Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Care Development, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tanzania Commission for Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Government of Equatorial Guinea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marathon Oil Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Noble Oil Services</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanaria Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial will evaluate safety and tolerability as well as the vaccine-induced
      humoral and cellular immune responses in healthy Tanzanian adults, adolescents, children, and
      infants who receive doses of 1.8x10^6, 9.0x10^5, 4.5x10^5 or 2.7x10^5 PfSPZ of PfSPZ Vaccine
      by direct venous inoculation (DVI),compared with control groups receiving normal saline (NS)
      placebo by DVI. In addition, as an exploratory objective, controlled human malaria infection
      (CHMI) will be used to assess efficacy in adults three weeks following immunization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center trial to assess the safety, tolerability and immunogenicity of PfSPZ
      Vaccine administered by direct venous inoculation (DVI) to healthy Tanzanian adults,
      adolescents, and children and infants. Ninety-nine healthy male and female; adults,
      adolescents, children and infant volunteers, aged from 6 months to 45 years, who live in the
      Bagamoyo Township will be enrolled based on pre-defined inclusion and exclusion criteria
      implemented according to international ethical standards.

      The safety and tolerability of PfSPZ Vaccine administered as three doses of either 9.0x10^5
      PfSPZ or 1.8x10^6 PfSPZ to healthy Tanzanian adults, adolescents, and children 6 years of age
      or older; and three doses of 4.5x10^5 PfSPZ or 9.0x10^5 PfSPZ to healthy Tanzanian children 1
      to 5 years of age and infants 6 to 11 months of age, in each case compared to NS controls,
      will be evaluated. In addition, as an exploratory objective, controlled human malaria
      infection (CHMI) will be used to assess efficacy in adults three weeks following
      immunization.

      Study Design: This is a single center trial with ten groups (Groups 1a/b: ages 18-45; Group
      2a/b: ages 11-17; Group 3a/b: ages 6-10; Group 4a/b: ages 1-5; and Group 5b/c: ages
      6months-11 months) each with 6 subjects receiving PfSPZ Vaccine and 3 subjects receiving NS
      and an eleventh smaller group (Group 5a: ages 6months-11months) with 3 subjects receiving
      PfSPZ Vaccine; two of these groups contain adult volunteers (Group 1a/b) and will have an
      additional 3 infectivity controls after the vaccination phase of the study. The adult
      volunteers will undergo CHMI 3 weeks after the last immunization.

      For the first immunization, two volunteers (out of six) in Group 1a will receive 9x10^5 of
      PfSPZ Vaccine by DVI as sentinels, to demonstrate safety and tolerability. At the same time,
      one (out of three) corresponding control volunteers will receive NS, in order to maintain
      blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting
      are not met, the remaining four volunteers in Group 1a will also receive a 9x10^5 PfSPZ dose
      of the vaccine and the remaining two placebo recipients will receive NS.

      After review of at least +14 days post vaccination safety data for Group 1a by the SMC, if
      there are no significant safety concerns, two volunteers (out of six) in Group 1b will
      receive 1.8x10^6 PfSPZ, and two volunteers (out of six) in each of the Groups 2a and 3a will
      receive 9x10^5 PfSPZ, of the PfSPZ Vaccine, to demonstrate safety and tolerability, and each
      of these sentinel groups will be joined by one corresponding NS control in order to maintain
      blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting
      are not met, the remaining four volunteers in Group 1b will receive 1.8x10^6 PfSPZ and the
      remaining four volunteers in each of Groups 2a and 3a will receive 9x10^5 PfSPZ of the PfSPZ
      Vaccine, and the remaining placebo recipients will receive NS.

      After review of at least +14 days post vaccination safety data for Groups 1b, 2a and 3a by
      the SMC, if there are no significant safety concerns, two volunteers (out of six) in each of
      the Groups 2b and 3b will receive 1.8x10^6 PfSPZ, those in Group 4a will receive 4.5x10^5
      PfSPZ and all 3 volunteers in Group 5a will receive 2.7x10^5 PfSPZ of PfSPZ Vaccine, to
      demonstrate safety and tolerability, and each of the sentinel groups (two volunteers from
      Groups 2b, 3b and 4a) will be joined by one NS control in order to maintain blinding.
      Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not
      met, the remaining four volunteers in Groups 2b, 3b and 4a will receive their appropriate
      dose of PfSPZ Vaccine (1.8x10^6 PfSPZ, 1.8x10^6 PfSPZ, and 4.5x10^5 PfSPZ, respectively), and
      the placebo recipients will receive NS.

      Escalation from the small group of infants, (Group 5a, n=3) receiving a single dose of
      2.7x10^5 PfSPZ, to the full group (Group 5b, n=6) receiving three doses of 4.5x10^5 PfSPZ,
      will proceed without SMC review if criteria for calling an ad hoc SMC meeting are not met.
      However, if the criteria are met, an ad hoc SMC meeting will be called to review the data,
      and dose escalation to 4.5x10^5 PfSPZ will be postponed until the recommendations of the SMC
      are available. The interval between the 2.7x10^5 PfSPZ small group and the 4.5x10^5 PfSPZ
      larger group will be a minimum of three days.

      After review of at least +14 days post vaccination, safety data for Groups 2b, 3b, 4a, 5a and
      5b by the SMC, if there are no significant safety concerns, two volunteers (out of six) in
      each of the Groups 4b and 5c will receive 9x10^5 PfSPZ, to demonstrate safety and
      tolerability. At the same time, one (out of three) corresponding control volunteers will
      receive NS, in order to maintain blinding. Approximately 24 hours later, provided criteria
      for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Group 4b and
      5c will receive 9x10^5 PfSPZ dose of the vaccine, and the placebo recipients will receive NS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and type of Adverse Events</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings post first immunization onwards.
Occurrence of solicited symptoms during a 7-day surveillance period after vaccination (day of vaccination (Vx) and +7 days post vaccination)
Occurrence of unsolicited symptoms during a 28-day surveillance period after each vaccination.
Occurrence of serious adverse events during the study period.
Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Antibodies against Pf proteins in volunteer sera</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1] by ELISA
Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA.
Analysis of antibodies to proteins in the Pf proteome array chip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of cellular immune responses against Pf proteins in volunteers</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Identification of number of vaccine induced PBMCs following Intracellular cytokine staining by flow cytometry after stimulation with PfSPZ or Pf-infected erythrocytes, peptide pools and P. falciparum infected primary human hepatocyte cell lines.
Identification of numbers of vaccine induced CD4 and CD8 T cells following FluoroSpot assay after stimulation with PfSPZ or Pf-infected erythrocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole genome expression profiles of volunteer</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Human gene expression profiling focusing on immune response genes in volunteers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of adult volunteers protected against CHMI following immunization</measure>
    <time_frame>28 days post CHMI</time_frame>
    <description>Evidence of vaccine-mediated protection against CHMI 3 weeks after last immunization in Groups 1 (adults) by preventing blood stage infection for 28 days (as detected by blood smear analysis and qPCR) following CHMI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic profiles of Pf parasites</measure>
    <time_frame>Screening uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Whole genome sequencing of Plasmodium falciparum following break through infections.</description>
  </other_outcome>
  <number_of_arms>23</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group 1a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18- 45 years; n=6; 3 doses of 9 x 10^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1a (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1a (CHMI controls)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>18- 45 years; n=3; volunteers will not receive any intervention, but will serve only as infectivity controls for the CHMI for Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18- 45 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b (CHMI controls)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>18- 45 years; n=3; volunteers will not receive any intervention, but will serve only as infectivity controls for the CHMI for Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>11-17 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>11-17 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-10 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-10 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-5 years; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4a (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-5 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-11 months; n=3; 1 dose of 2.7 x 10^5 PfSPZ Vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-11 months; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5c (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-11 months; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5c (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PfSPZ Vaccine</intervention_name>
    <description>Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)</description>
    <arm_group_label>Group 1a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 1b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 2a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 2b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 3a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 3b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 4a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 4b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 5a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 5b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 5c (PfSPZ Vaccine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.9% Sodium chloride</description>
    <arm_group_label>Group 1a (normal saline)</arm_group_label>
    <arm_group_label>Group 1b (normal saline)</arm_group_label>
    <arm_group_label>Group 2a (normal saline)</arm_group_label>
    <arm_group_label>Group 2b (normal saline)</arm_group_label>
    <arm_group_label>Group 3a (normal saline)</arm_group_label>
    <arm_group_label>Group 3b (normal saline)</arm_group_label>
    <arm_group_label>Group 4a (normal saline)</arm_group_label>
    <arm_group_label>Group 4b (normal saline)</arm_group_label>
    <arm_group_label>Group 5b (normal saline)</arm_group_label>
    <arm_group_label>Group 5c (normal saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PfSPZ Challenge (for CHMI)</intervention_name>
    <description>live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge</description>
    <arm_group_label>Group 1a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 1a (normal saline)</arm_group_label>
    <arm_group_label>Group 1a (CHMI controls)</arm_group_label>
    <arm_group_label>Group 1b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 1b (normal saline)</arm_group_label>
    <arm_group_label>Group 1b (CHMI controls)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females, based on clinical and laboratory findings

          -  From the age 6 months to 45 years

          -  Adults with a Body Mass Index (BMI) 18 to 30 Kg/m2; or adolescents, children and
             infants with Z-score of the selected indicator ([weight-for-height], [(height and BMI)
             for age]) category within Â±2SD as detailed in protocol

          -  Long term (at least one year) or permanent residence in the Bagamoyo town or nearby
             villages

          -  Agreement to release medical information and to inform the study doctor concerning
             contraindications for participation in the study

          -  Willingness to be attended to by a study clinician and take all necessary medications
             prescribed during study period

          -  Agreement to provide contact information of a third party household member or close
             friend to study team

          -  Availability through mobile phone 24 hours during the entire study period

          -  Agreement not to participate in another clinical trial during the study period

          -  Agreement not to donate blood during the study period

          -  Able and willing to complete the study visit schedule over the study follow up period,
             including the hospitalizations required for protocol compliance

          -  Willingness to undergo HIV, hepatitis B (HBV) and hepatitis C (HCV) tests

          -  Volunteer (subjects 18 years of age and older) and parent or guardian signing informed
             consent (for subjects &lt;18 years of age) is able to demonstrate their understanding of
             the study by responding correctly to 10 out of 10 true/false statements (in a maximum
             of two attempts for those who failed to respond correctly to all true/false statements
             in the first attempt)

          -  Signed written informed consent, in accordance with local practice, provided by adult
             volunteers, parents or legal representatives and relevant assent for children
             participants as applicable

          -  Free from malaria parasitaemia by blood smear at enrolment

          -  Free from helminth infections at enrolment, or diagnosed with helminthes and treated
             appropriately to eliminate infestation

          -  Female volunteers aged 9 years and above must be non-pregnant (as demonstrated by a
             negative serum pregnancy test), and provide consent / assent of their willingness to
             take protocol-defined measures not to become pregnant during the study and safety
             follow-up period

        Exclusion Criteria:

          -  Previous receipt of an investigational malaria vaccine or drug in the last 5 years

          -  Participation in any other clinical study involving investigational medicinal products
             within 30 days prior to the onset of the study or during the study period

          -  History of arrhythmias or prolonged QT-interval or other cardiac disease, or
             Clinically significant abnormalities in electrocardiogram (ECG) at screening

          -  Positive family history in a 1st or 2nd degree relative for cardiac disease at age &lt;50
             years old

          -  A history of psychiatric disease

          -  Suffering from any chronic illness including; diabetes mellitus, cancer or HIV/AIDS

          -  Any confirmed or suspected immunosuppressive or immune-deficient condition, including
             asplenia

          -  History of drug or alcohol abuse interfering with normal social function

          -  The use of chronic immunosuppressive drugs or other immune modifying drugs within
             three months of study onset (inhaled and topical corticosteroids are allowed) and
             during the study period

          -  Any clinically significant deviation from the normal range in biochemistry or
             hematology blood tests or in urine analysis

          -  Positive HIV, hepatitis B virus or hepatitis C virus tests

          -  Volunteers who are suspected as having clinically active TB by history or physical
             examination with positive QuantiFERON-TB Gold Test In-Tube assay

          -  Symptoms, physical signs and laboratory values suggestive of systemic disorders
             including renal, hepatic, blood, cardiovascular, pulmonary, skin, immunodeficiency,
             psychiatric, and other conditions which could interfere with the interpretation of the
             study results or compromise the health of the volunteers

          -  Any medical, social condition, or occupational reason that, in the judgment of the
             investigator, is a contraindication to protocol participation or impairs the
             volunteer's ability to give informed consent, increases the risk to the volunteer
             because of participation in the study, affect the ability of the volunteer to
             participate in the study or impair interpretation of the study data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Said Jongo, MD, MMED</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ifakara Health Institute (IHI), Bagamoyo, Tanzania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagamoyo Research and Training center of the Ifakara Health Institute</name>
      <address>
        <city>Bagamoyo</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PfSPZ Vaccine</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

